Mefenamic Acid Manufacturing Plant Project Report 2026: Cost Analysis, ROI, and Feasibility Insights

Mefenamic Acid is manufactured through a copper-catalysed C–N condensation reaction between 2-chlorobenzoic acid and 2,3-dimethylaniline. Copper(II) acetate can be used as the catalyst, followed by acidification, filtration, purification, crystallisation, and drying. Industrial processes generally operate at about 104–130 degree Celsius, depending on the specific process and catalyst system.

The key feedstocks are 2-chlorobenzoic acid, 2,3-dimethylaniline, and a copper-based catalyst. Together, the principal organic feedstocks typically account for approximately 55% to 70% of total raw-material expenditure, with the exact share depending on feedstock prices, catalyst loading, yield, and solvent recovery.

Process and plant equipment, including glass-lined reactors, crystallisers, centrifuges, purification equipment, and industrial dryers, represents approximately 60% to 70% of total CAPEX. The remaining 30% to 40% generally covers utilities, civil works, storage, material handling, effluent treatment, laboratory facilities, and other supporting infrastructure.

The major manufacturing-cost drivers are the price and purity of 2-chlorobenzoic acid and 2,3-dimethylaniline, copper catalyst consumption, reaction yield, solvent consumption and recovery, purification losses, energy, and waste treatment. The principal organic feedstocks can account for approximately 55% to 70% of raw-material expenditure.

Asia-Pacific is the major manufacturing region for Mefenamic Acid, with India and China serving as important API production and supply bases. Asia-Pacific accounts for approximately 45% to 55% of global supply, although this figure represents supply rather than a separately measured share of installed global production capacity. India and China are also identified as key sourcing origins for Mefenamic Acid API.

Mefenamic Acid API manufacturing requires GMP-compliant production, validated processes, controlled handling of chemical raw materials and catalysts, and testing for purity and impurities in accordance with applicable pharmacopoeial requirements. Facilities must also manage solvent emissions, copper-containing waste, wastewater, and solid residues through appropriate treatment and disposal systems; solvent recovery and catalyst recycling can reduce waste and resource consumption.